38 research outputs found
Single-Cell Genetic Analysis Reveals Insights into Clonal Development of Prostate Cancers and Indicates Loss of PTEN as a Marker of Poor Prognosis
Gauging the risk of developing progressive disease is a major challenge in prostate cancer patient management. We used genetic markers to understand genomic alteration dynamics during disease progression. By using a novel, advanced, multicolor fluorescence in situ hybridization approach, we enumerated copy numbers of six genes previously identified by array comparative genomic hybridization to be involved in aggressive prostate cancer [TBL1XR1, CTTNBP2, MYC (alias c-myc), PTEN, MEN1, and PDGFB] in six nonrecurrent and seven recurrent radical prostatectomy cases. An ERG break-apart probe to detect TMPRSS2-ERG fusions was included. Subsequent hybridization of probe panels and cell relocation resulted in signal counts for all probes in each individual cell analyzed. Differences in the degree of chromosomal and genomic instability (ie, tumor heterogeneity) or the percentage of cells with TMPRSS2-ERG fusion between samples with or without progression were not observed. Tumors from patients that progressed had more chromosomal gains and losses, and showed a higher degree of selection for a predominant clonal pattern. PTEN loss was the most frequent aberration in progressers (57%), followed by TBL1XR1 gain (29%). MYC gain was observed in one progresser, which was the only lesion with an ERG gain, but no TMPRSS2-ERG fusion. According to our results, a probe set consisting of PTEN, MYC, and TBL1XR1 would detect progressers with 86% sensitivity and 100% specificity. This will be evaluated further in larger studies
Anti-CD20 Monoclonal Antibody (Rituximab) and Cidofovir as Successful Treatment of an EBV-Associated Lymphoma with CNS Involvement
Background: Epstein-Barr virus(EBV)-associated posttransplant lymphoproliferative disease (PTLD) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Especially in cases with involvement of the central nervous system (CNS) treatment is difficult because the efficacy of most chemotherapeutic agents as well as EBV-specific cytotoxic donor T cells in liquor is uncertain. In the last years the anti-CD20 monoclonal antibody Rituximab was intensively investigated in the treatment of EBV-PTLD. However, only 8 patients with B-cell lymphoma and CNS involvement treated with Rituximab were reported. Case Report: A 24-year-old female patient with acute T-lymphoblastic leukemia in second complete remission had received allogeneic, unrelated, T-cell depleted HSCT. 10 months later an EBV-associated PTLD was diagnosed. Beside peripheral lymphomas and B symptoms the patient showed neurological symptoms. Examination of the cerebrospinal fluid (CSF) revealed a meningeosis lymphoblastica caused by the EBV lymphoma. Treatment with Rituximab and the antiviral drug Cidofovir led to complete remission with regression of the peripheral lymphomas and disappearance of the neurological symptoms. In addition, the PCR control on EBV DNA became negative in the plasma as well as in CSF. Conclusion: The combination of Rituximab and Cidofovir appears as an interesting alternative treatment in patients with EBV-associated PTLD and CNS involvement.Hintergrund: Die Epstein-Barr-Virus(EBV)-assoziierte Posttransplantations-lymphoproliferative Disease (PTLD) ist eine gefürchtete Komplikation nach allogener hämatopoetischer Stammzelltransplantation (HSCT). Insbesondere bei Befall des zentralen Nervensystems (ZNS) ist die Behandlung auf Grund der unsicheren Liquorwirksamkeit der meisten Chemotherapeutika als auch von EBV-spezifischen zytotoxischen T-Spenderzellen schwierig. Der monoklonale Anti-CD20-Antikörper Rituximab wurde in den letzten Jahren bei Patienten mit EBV-PTLD intensiv untersucht. Allerdings wurde bislang lediglich von 8 Patienten mit ZNS-Befall eines B-Zell-Lymphoms berichtet, bei denen eine Therapie mit Rituximab erfolgte. Kasuistik: Eine 24-jährige Patientin hatte wegen einer akuten T-lymphoblastischen Leukämie in zweiter kompletter Remission eine allogen-unverwandte, T-Zelldepletierte HSCT erhalten. 10 Monate später wurde eine EBV-assoziierte PTLD diagnostiziert. Neben peripheren Lymphomen und B-Symptomen zeigte die Patientin neurologische Symptome. Die Liquoruntersuchung erbrachte den Befund einer Meningeosis lymphoblastica im Rahmen des EBV-Lymphoms. Die Behandlung mit Rituximab und dem Virustatikum Cidofovir führte zu einer kompletten Remission mit Rückbildung der peripheren Lymphome und Verschwinden der neurologischen Symptomatik. Außerdem wurde die PCR-Kontrolle auf EBV-DNA sowohl im Plasma als auch im Liquor negativ. Schlussfolgerung: Die Kombination von Rituximab und Cidofovir erscheint als eine interessante Therapiealternative für Patienten mit EBV-assoziierter PTLD und ZNS-Befall.Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
Density of CD8-positive tumor-infiltrating T-lymphocytes is an independent prognostic factor in adenocarcinoma of the esophagogastric junction
Tumor-infiltrating lymphocytes (TILs) have
commonly been associated with markedly improved
prognosis in a variety of human cancers, including
carcinomas of the upper and lower gastrointestinal tract.
Especially the presence of T-cells (cytotoxic as well as
helper cells) seems to define a subgroup of patients with
prolonged overall and event-free survival. The density of
TILs was assessed via immunohistochemistry for CD8
and CD103 in a population of 228 adenocarcinomas of
the esophagogastric junction. Density of CD8+ Tlymphocytes was inversely correlated with depth of
tumor infiltration (p=0.013) while no correlation with
any of the analyzed clinicopathologic factors could be
established for CD103-density. High density of CD8-
positive T-cells additionally showed significantly longer
overall survival (OS) with a p-value of 0.024 while
density of CD103+ cells was associated with prolonged
tumor free survival (p-value 0.011). Independence could
be demonstrated applying Cox proportional hazard
analysis (Hazard Ratio 0.742; 95%-Confidence Interval
0.579-0.951; p=0.019). High density of CD8-positive Tlymphocytes identifies a patient subgroup with
significantly prolonged overall survival, is correlated
with tumor stage and might open up new therapeutic
possibilities via immunomodulating drugs
Expression of cyclooxygenase-2 has no impact on survival in adenocarcinoma of the esophagogastric junction but is associated with favourable clinicopathologic features
Background. COX-2 expression induces
carcinogenesis and is thought to be an adverse
prognostic factor in gastric carcinomas while the
prognostic value of DNA mismatch repair (MMR) is still
controversial. Concerning adenocarcinomas of the
esophagogastric junction, no comprehensive data
regarding either factors are available as of yet.
Objective. We assessed expression of COX-2,
MLH1 and MSH2 in adenocarcinoma of the
esophagogastric junction in relation to patients’ survival
and various clinicopathologic features.
Design. Immunohistochemical studies (using
antibodies against COX-2, MLH1 and MSH2) were
performed in a study population of 228 tumours. Followup data was available for all patients with a mean
follow-up time of 42.8 months.
Results. 78 (34.2%) tumours were COX-2 negative,
148 (64.9%) showed COX-2 positivity. Assessment of
COX-2 expression and clinicopathologic features
revealed an inverse correlation with depth of tumour
invasion and number of metastatic lymph nodes
(p=0,021 and p=0,004, respectively). No correlation
with other features could be demonstrated. 62 cases
(27.2%) showed loss of DNA repair enzymes MLH1
and/or MSH2. MMR differed significantly between
COX-2 positive and negative cases (p=0,028). KaplanMeier survival analyses revealed no impact on patients’
survival for COX-2 expression or MMR status (p=0.837
and p=0.972, respectively).
Conclusions. Expression of COX-2 in adenocarcinomas of the esophagogastric junction seems to
have no prognostic effect or impact on patients’ survival
but is associated with favourable clinico-pathologic
factors. MMR deficiency was more frequent in COX-2
negative tumours, but MMR status had no impact on
survival and patients’ outcome whatsoeve
Recommended from our members